Tiopronin-cysteine disulfide

Cat. No.: HY-131516 Purity: 96.78%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Tiopronin-cysteine disulfide is a soluble disulfide metabolite/derivative of Tiopronin (HY-B0373) formed by reaction of Tiopronin with cystine. Tiopronin-cysteine disulfide reduces cystine crystal formation in cystinuria. Tiopronin-cysteine disulfide can be used for the research of cystinuria.

For research use only. We do not sell to patients.

Tiopronin-cysteine disulfide Chemical Structure

CAS No. : 77591-18-5

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	Get quote
10 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Tiopronin-cysteine disulfide (2-20 mM; 0-48 h) forms as a soluble complex via disulfide bond exchange between Tiopronin (or Tiopronin released from Tiopronin-NO after NO cleavage) and cystine in artificial, healthy human, and cystinuria patient urine, with complete conversion observed at tested concentrations and incubation times, and this complex drives enhanced cystine solubility in urine^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

282.34

Formula

C₈H₁₄N₂O₅S₂

CAS No.

77591-18-5

Appearance

Solid

Color

White to off-white

SMILES

N[C@H](C(O)=O)CSSC(C(NCC(O)=O)=O)C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Purity & Documentation

Purity: 96.8%

Select Batch:

Data Sheet (264 KB) SDS (251 KB)

COA (244 KB)

Handling Instructions (2659 KB)

References

[1]. Lindell A, et al. Clinical course and cystine stone formation during tiopronin treatment. Urol Res. 1995;23(2):111-117. [Content Brief]

[2]. Kumar A, et al. Chemical Modification of Tiopronin for Dual Management of Cystinuria and Associated Bacterial Infections. ACS Appl Mater Interfaces. 2023;15(37):43332-43344. [Content Brief]